Blood Borne Viruses (HIV, HepB & HepC)

Special Precautions/Comments:

N.B. Please clearly label all known high risk samples with Danger of Infection stickers.

Samples that are grossly lipaemic, icteric or haemolysed will not be processed and a repeat sample will be requested.

Interferences:  Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 676 IU/mL.

In rare cases, interference due to extremely high titres of antibodies to analyte‑specific antibodies or ruthenium can occur. These effects are minimised by suitable test design.

Extremely high titres of antibodies to streptavidin can occur in isolated cases and cause interference.

Method:  Chemiluminescent testing of serum and plasma samples. Calibration: Roche QC material.  EQA scheme: NEQAS EQA schemes IQC: Roche individual QC for each assay.

Interpretation:  Results will be reported as PositiveEquivocal or Negative.

New positive/equivocal results will be referred to Freeman Road serology department for further/conformation testing. For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

Additional Information: